Finally, we performed further independent clinical validation in the I-SPY2 breast cancer neoadjuvant chemotherapy adaptive trial (N = 987) confirming the significant association between TP53-loss phenocopy status and pathologic complete response. Here, TP53 is linked to breast carcinoma.